Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26685970 | 1.00 | CYP3A4 (0.39) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL30755776 | 0.82 | MEN1 (0.33) | — | |
| SCHEMBL30755981 | 0.78 | CYP3A4 (0.39) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL31492995 | 0.75 | HSP90AA1 (0.34) | CYP2D6 | |
| SCHEMBL31581581 | 0.73 | — | — | |
| SCHEMBL18711831 | 0.72 | CYP3A4 (0.43) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL6181347 | 0.72 | — | — | |
| SCHEMBL18068094 | 0.71 | CYP3A4 (0.50) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL1706014 | 0.71 | NOS3 (0.39) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL31543131 | 0.70 | NOS3 (0.36) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4554938-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024015497-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | CYP3A4 3635/4885CYP2D6 2212/4885TSHR 846/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CYP3A4 2650/4885CYP2D6 823/4885TSHR 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.